Slide 1: Stevanato Group Q3 2023 Financial Results
Exhibit 99.1 Stevanato Group Q3 2023 Financial Results October 31, 2023
Slide 2: Safe Harbor Statement
Safe Harbor Statement Forward-Looking Statements This presentation may include forward-looking statements. The words "expect,” "reiterating,” “continue,” “assumes," "rise," “position,” "strong," "increased," "benefiting," "expected," "remain," "can," "shift," "growing," "deliver," "are delivering,"
Slide 3: Earnings Call Speakers
Stevanato Group Second Quarter 2023 Financial Results Earnings Call Q3 2023 Financial Results Franco Franco Marco Lisa Stevanato Moro Dal Lago Miles Executive Chairman CEO CFO SVP IR 3
Slide 4: Franco Stevanato, Executive Chairman
Q3 2023 Financial Results Franco Stevanato Executive Chairman 4
Slide 5: Substantial Progress in Building Durable Organic Growth
Substantial Progress in Building Durable Organic Growth Double-digit revenue growth and adj. EBITDA margin of 27.5% in Q3 23. Q3 23 Engineering Segment revenue fell short of our expectations due to the timing of revenue. We remain confident that we can achieve our FY 2023 Guidance. Business fundamen
Slide 6: Marco Dal Lago, Chief Financial Officer
Q3 2023 Financial Results Marco Dal Lago Chief Financial Officer 6
Slide 7: Q3 2023: Financial Highlights
Q3 2023: Financial Highlights Q3 2023 Revenue (€ Million) HVS non-HVS Revenue increase driven by growth in both segments (on CC basis, +13% yoy) • Revenue was below what we expected for Q3 sales at the time of our Q3 2023 Financial Results +11% Capital Markets Day. Since then, revenue tied to specif
Slide 8: Q3 2023 Segment Trends
Q3 2023 Segment Trends Biopharmaceutical and Diagnostic Solutions Segment (BDS) +6% Q3 revenue increased 6% yoy (8% on CC basis) Q3 2023 Financial Results • Excluding Covid-19 related revenue, BDS grew approx. 23% REVENUE* 207 219 (€ Million) • Growth driven by 16% increase in High-Value Solutions Q
Slide 9: Balance Sheet with Financial Flexibility
Balance Sheet with Financial Flexibility At Quarter Ended September 30, 2023 Q3 2023 Financial Results € 227.5M € 64.8M Net Debt* Total Cash and Cash Equivalents In Third Quarter 2023 (€ 97.8M) € 33.5M € 107.2M Free Cash Flow* Net Cash Generated CapEx* from Operations __________ * Free Cash Flow, Ne
Slide 10: Reiterating 2023 Guidance
Reiterating 2023 Guidance 2023 Guidance Q3 2023 Financial Results Revenue € 1.085B - € 1.115B Implied Growth 10% - 13% Adjusted DEPS* € 0.58 - € 0.62 Adjusted EBITDA* € 291.8M - € 303.8M Weighted Avg. Shares Outstanding 265.4M 2023 Guidance assumes: • Capital expenditures in the range of 35% to 40%
Slide 11: Franco Moro, Chief Executive Officer
Q3 2023 Financial Results Franco Moro Chief Executive Officer 11
Slide 12: Engineering Segment
Engineering Segment Actions to satisfy the increased demand • Adding resources Q3 2023 FInancial Results Stronger demand compared to • Enhancing technical competencies, to help one year ago drive digitalization Growth in Biologics driving demand for • Implementing continuous process visual inspectio
Slide 13: Biopharmaceutical and Diagnostic Solutions Segment (BDS)
Biopharmaceutical and Diagnostic Solutions Segment (BDS) Core Drug Containment Solutions (DCS) business grew approx. 10% yoy in Q3 23. Excluding Covid-19, DCS grew more than 25% in Q3 23 BDS Segment – Full Year 2023 growth breakdown • Robust demand driven by the need for high-performance drug ILLUST
Slide 14: Reiterating our 2023 Guidance
Reiterating our 2023 Guidance, as we continue to see positive long-term trends. We are operating in an environment of favorable demand, growing end markets and multi-year secular drivers. Q3 2022 FInancial Results Global HVS R&D Multi-Year Expansion Growth Innovation Pipeline 14
Slide 15: Notes to Non-GAAP Financial Measures
Notes to Non-GAAP Financial Measures This presentation contains non-GAAP financial measures. Please refer to the tables included in this presentation for a reconciliation of non- Q3 2023 Financial Results GAAP measures. Management monitors and evaluates our operating and financial performance using
Slide 16: Reconciliation of Non-GAAP Financial Measures
Reconciliation of Non-GAAP Financial Measures Reconciliation of Revenue to Constant Currency Revenue (Amounts in € millions) (Unaudited) Q3 2023 Financial Results Biopharmaceutical Biopharmaceutical and and Three months ended September 30, 2023 Diagnostic Solutions Engineering Nine months ended Sept
Slide 17: Reconciliation of Non-GAAP Financial Measures
Reconciliation of Non-GAAP Financial Measures Reconciliation of Reported and Adjusted EBITDA, Operating Profit, Income Taxes, Net Profit and Diluted EPS (Unaudited) (Amounts in € millions, except per share data) Q3 2023 Financial Results Operating Income Three months ended September 30, Operating In
Slide 18: Reconciliation of Non-GAAP Financial Measures
Reconciliation of Non-GAAP Financial Measures Free Cash Flow Net Cash / (Net Debt) (Amounts in € millions) (Amounts in € millions) (Unaudited) (Unaudited) For the three months For the nine months Q3 2023 Financial Results ended September 30, ended September 30, As of September 30, As of December 31,
Slide 19: Reconciliation of Non-GAAP Financial Measures
Reconciliation of Non-GAAP Financial Measures Q3 2023 Financial Results Reconciliation of 2023 Guidance for Adjusted EBITDA, Adjusted Operating Profit, Adjusted Net Profit and Adjusted Diluted EPS (Amounts in € millions, except per share data) (Unaudited) * Operating Revenue EBITDA Net Profit Dilute